Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.


Journal

International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237

Informations de publication

Date de publication:
07 2019
Historique:
received: 27 11 2018
accepted: 21 03 2019
pubmed: 20 4 2019
medline: 18 8 2020
entrez: 20 4 2019
Statut: ppublish

Résumé

To estimate the conditional biochemical recurrence-free probability and to develop a predictive model according to the disease-free interval for men with clinically localized prostate cancer treated with minimally invasive radical prostatectomy. The study population consisted of 3576 consecutive patients who underwent laparoscopic radical prostatectomy and 2619 men treated with robotic radical prostatectomy in the past 15 years at Institute Mutualiste Montsouris, Paris, France. Biochemical recurrence was defined as serum prostate-specific antigen ≥0.2 ng/dL. Univariable and multivariable survival analyses were carried out to identify the prognostic factors for overall free-of-biochemical recurrence probability and conditional survival with respect to the years from surgery without recurrence. A detailed nomogram for the static and dynamic prognosis of biochemical recurrence was developed and internally validated. The median follow-up period was 8.49 years (interquartile range 4.01-12.97), and 1148 (19%) patients experienced biochemical recurrence. Significant variables associated with biochemical recurrence in the multivariable model included preoperative prostate-specific antigen, positive surgical margins, extracapsular extension, pathological Gleason ≥4 + 3 and laparoscopic surgery (all P < 0.001). Conditional survival probability decreased with increasing time without biochemical recurrence from surgery. When stratified by prognosis factors, the 5- and 10-year conditional survival improved in all cases, especially in men with worse prognosis factors. The concordance index of the nomogram was 0.705. Conditional survival provides relevant information on how prognosis evolves over time. The risk of recurrence decreases with increasing number of years without disease. An easy-to-use nomogram for conditional survival estimates can be useful for patient counseling and also to optimize postoperative follow-up strategies.

Identifiants

pubmed: 31001870
doi: 10.1111/iju.13982
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-730

Informations de copyright

© 2019 The Japanese Urological Association.

Auteurs

Silvia García-Barreras (S)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Rafael Sanchez-Salas (R)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Carlos Mejia-Monasterio (C)

Laboratory of Physical Properties, School of Agricultural, Food and Biosystems Engineering, Technical University of Madrid, Madrid, Spain.

Fabio Muttin (F)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Fernando Secin (F)

Department of Urology, CEMIC University Hospital, Buenos Aires, Argentina.

Paolo Dell'Oglio (P)

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Igor Nunes-Silva (I)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Victor Srougi (V)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Eric Barret (E)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

François Rozet (F)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Dominique Prapotnich (D)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Xavier Cathelineau (X)

Department of Urology, Institute Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH